Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
about
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphomaThe impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trialsPredicting neutropenia risk in patients with cancer using electronic data.Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline.Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisEffectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.Evidence-based use of colony-stimulating factors in elderly cancer patients.Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial.High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial.Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical OncRecombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).Patients with osteosarcoma and soft tissue sarcoma might become "cancer refugees" in some Japanese regional cities.
P2860
Q24240753-BAE830CB-5A6A-4A59-8A83-B6549E76ACD1Q27008080-3327345D-A7B4-404A-B345-67CBC489FE1CQ31131362-EDB519C9-5328-4261-81EE-7B9599FD95C9Q33379481-5AF6C97D-1A2E-40D1-86DB-6B6A5BEFCB8CQ34029496-8B1777B2-4939-41CB-A206-F05B468651E7Q34553998-DFFCB5CA-5541-4981-83E1-3069BCC512E6Q35599074-75F4F544-7812-4291-B21F-2D4F29CDA118Q36674048-5C679792-1A00-47C8-BB0E-FDABCA4A6F36Q37886394-44541650-F7FD-4D5E-9737-2EF5B6904680Q38006021-4D7A8285-D7C6-4D86-95B8-2370A4AA5838Q42223844-D0F9388A-695F-44C3-B462-8B34818DDF58Q51546513-5C40E229-E365-4DA5-AADA-4AAF3ECA0CECQ55024248-A1B3FEAA-54B9-400D-8E0B-E166EE9E5C75
P2860
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
description
1995 nî lūn-bûn
@nan
1995 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Efficacy of lenograstim on hem ...... s on treatment dose-intensity.
@ast
Efficacy of lenograstim on hem ...... s on treatment dose-intensity.
@en
type
label
Efficacy of lenograstim on hem ...... s on treatment dose-intensity.
@ast
Efficacy of lenograstim on hem ...... s on treatment dose-intensity.
@en
prefLabel
Efficacy of lenograstim on hem ...... s on treatment dose-intensity.
@ast
Efficacy of lenograstim on hem ...... s on treatment dose-intensity.
@en
P2093
P1476
Efficacy of lenograstim on hem ...... s on treatment dose-intensity.
@en
P2093
B Chevallier
C Chevreau
C Maugard-Louboutin
D Cupissol
F Bonichon
I Krakowski
P304
P356
10.1200/JCO.1995.13.10.2629
P407
P577
1995-10-01T00:00:00Z